Jeito Capital appoints Pascal Touchon as Operating Partner

• Pascal Touchon will reinforce Jeito’s expertise by bringing over 35 years of global experience in drug development, commercial activities, operational and strategic leadership at major international pharmaceutical groups and biotech companies.
• He will support the execution of Jeito’s differentiated and proven investment strategy and help accelerate the clinical and commercial development of its portfolio companies. This reflects a shared ambition to bring high-quality innovation faster to patients.

Paris, France, June 2nd, 2025 – Jeito Capital (“Jeito”), a global leading independent Private Equity fund dedicated to biopharma, is pleased to announce the appointment of Pascal Touchon, MBA, DVM, as Operating Partner.

Pascal has served as a Special Advisor to Jeito since 2022 and represents the firm on the Board of Directors of portfolio company CatalYm. As Operating Partner, he will deepen his involvement with the firm, bringing over 35 years of biopharmaceutical experience, including senior positions in the US and at global companies such as Novartis, Servier and GSK. He will contribute to value creation for Jeito’s multidisciplinary team and portfolio companies through his strategic expertise and operational experience across portfolio management, as well as clinical and commercial development of medical innovations.

This appointment reflects Jeito’s continued focus on advancing breakthrough therapies in areas of significant unmet medical need, with two-thirds of known diseases still lacking effective treatment.

“Pascal’s expanded role reflects our shared commitment to advancing medical innovation for the benefit of patients,” said Dr. Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital. “His experience and deep understanding of the pharmaceutical industry are especially valuable as we continue to build momentum. He’s already played an active role across our team and portfolio, and this next step is a natural evolution of a trusted and productive collaboration. We look forward to continuing to work together to strengthen Jeito’s leadership and support the growth of tomorrow’s global biopharma leaders.”

“I’m honored by the trust Jeito has placed in me. I share their ambition for innovation and  excellence through a collective commitment dedicated to patients,” said Pascal Touchon, Operating Partner at Jeito Capital. “I’m excited to continue contributing to a differentiating strategy that is already demonstrating its value, for both patients and society.”

Alongside his new role at Jeito, Pascal continues to serve as Chairman of the Board of Atara Biotherapeutics (Nasdaq: ATRA) and as an Independent Director on the Board of Ipsen (Euronext: IPN, ADR: IPSEY), Medincell (Euronext Paris: MEDCL), CDR-Life[1], as well as representing Jeito on the Board of CatalYm[1].

Throughout his professional journey over more than 35 years, Pascal has remained dedicated to transforming the lives of patients with serious medical conditions through his passion for pioneering science, collaborative leadership, and a steadfast commitment to excellence.

Before joining Jeito, Pascal was CEO of Atara Biotherapeutics (Nasdaq: ATRA) in California from 2019 to 2024, where he led the company’s transformation into a leader in cell therapy, obtaining in 2022 the first-ever regulatory approval for an allogeneic T-cell therapy, EBVALLO® (tabelecleucel). He became Chairman of the company in 2024.

Before joining Atara, Pascal was Senior Vice President and Global Head of Cell & Gene at Novartis Oncology, where he led the development, regulatory approval and global launch of KYMRIAH® (tisagenlecleucel), the first CAR-T therapy approved in the US. He also served previously as Global Head of Strategy and Business Development for Oncology and was a member of the Novartis Oncology Executive Committee. Earlier in his career, he held various roles across research, marketing, general management of subsidiaries and geographic areas, strategy and business development at Servier and GSK.

He has previously served on the boards of Genoptix, Navigate Biopharma Services, and Cogen Therapeutics. Pascal holds a Doctorate in Veterinary Medicine from Paul Sabatier University (Toulouse, France), a DESS in Management from IAE Toulouse, and an MBA from INSEAD.

[1] CDR Life and CatalYm are Jeito portfolio companies.

About Jeito Capital

Jeito Capital is a global leading Private Equity fund with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access globally, especially in Europe and the United States. Jeito has built a diversified portfolio of clinical biopharmas with cutting-edge innovations addressing high unmet needs. Jeito Capital is based in Paris with a presence in Europe and the United States.

For more information, please visit www.jeito.life or follow us on LinkedIn.

For further information please contact:

Maior
Stéphanie Elbaz
stephanie.elbaz@maior-conseil.com
Tel: +33 6 46 05 08 07